Kane Biotech (KNE) Q1 2026 earnings summary

Executive summary

• Revenue for Q1 2026 was $43,218, down from $412,513 in Q1 2025, reflecting a shift to human wound care and early commercialization of revyve products.

• Net loss improved to $714,827 from $1,218,497 year-over-year, driven by lower operating expenses and a disciplined cost structure.

• Strategic focus is on accelerating commercialization of the revyve wound care portfolio in North America.

Financial highlights

• Gross loss for Q1 2026 was $3,899, compared to a gross profit of $42,447 in Q1 2025, due to early commercialization and market build-out.

• Operating expenses decreased to $669,402 from $1,203,505 year-over-year, reflecting cost reductions in staffing, incentives, and product development.

• Cash at March 31, 2026 was $395,058, with additional capital raised after quarter-end.

Outlook and guidance

• Focus remains on converting commercial momentum into accelerating revenues and delivering long-term shareholder value.

• Management believes the company is at an inflection point in its commercialization journey.